Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment

Area of Science:

• Oncology
• Epigenetics
• Immunology

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) presents significant heterogeneity, with approximately one-third of patients experiencing relapse or refractory disease despite advancements.
• Epigenetic mechanisms, including chromatin remodeling, DNA methylation, histone modifications, and non-coding RNAs, are increasingly recognized as crucial in DLBCL pathogenesis.
• These epigenetic alterations influence oncogenesis, tumor progression, and therapeutic resistance in DLBCL.

Purpose of the Study:

• To review the critical interplay between DLBCL evolution and epigenetic mechanisms over the past decade.
• To elucidate the role of epigenetic modifications in both lymphoma cells and the tumor microenvironment (TME).
• To highlight the potential of epigenetic therapies for DLBCL treatment.

Main Methods:

• Comprehensive literature review focusing on recent findings in DLBCL epigenetics.
• Analysis of epigenetic alterations in lymphoma cells and immune cells within the TME.
• Synthesis of information on the development and implications of epigenetic therapies.

Main Results:

• Epigenetic dysregulation is a key driver in DLBCL development, progression, and resistance to therapy.
• Epigenetic changes affect not only lymphoma cells but also the immune cell network within the TME.
• The study of epigenetic mechanisms in the TME's immune cells remains an area requiring further investigation.

Conclusions:

• Epigenetic modifications are central to DLBCL biology and offer promising therapeutic targets.
• Understanding the dual impact of epigenetics on lymphoma and immune cells in the TME is essential for effective treatment strategies.
• Further research into TME-focused epigenetic therapies holds significant potential for improving patient outcomes in DLBCL.